AI in Pharma Shows Promise With Faster Development, Lower Costs
SMRTR summary
AI is revolutionizing pharmaceutical research, potentially reducing drug development timelines and costs. The U.S. National Science Foundation's $75 million investment in five biofoundries, including the AI-driven RNA Foundry, aims to streamline drug development processes. AI can accelerate drug discovery, improve clinical trial efficiency, and potentially lower drug prices, benefiting both pharmaceutical companies and consumers.
SMRTR provides this summary for quick context. The original article belongs to PYMNTS.
Read the original article